Please login to the form below

Not currently logged in
Email:
Password:

AZ's Mene Pangalos joins Precision Medicine Catapult board

Has also been appointed a fellow at the University of Cambridge
Mene Pangalos

AstraZeneca's Mene Pangalos, executive VP of IMED Biotech, has been appointed in two new positions based in Cambridge.

Pangalos will join the board of the Precision Medicine Catapult, the newly established centre in Cambridge designed to shape the future of precision medicine in the UK.

In his role as non-executive director, Pangalos will provide a pharmaceutical industry perspective on how to ensure the UK can remain at the cutting edge of precision medicine.

Additionally, Pangalos has also been appointed an as official fellow of Clare Hall College in the University of Cambridge.

Pangalos said: “I'm delighted to receive these two appointments. Although they are a great personal honour, I believe they are testament to the quality of our science, our pioneering approach to personalised healthcare and our long standing commitment to strengthening the UK life science sector.”    

13th November 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics